

The Contract Development Manufacturing Organization of the 21st Century

Combined Forces to Serve as the Biopharmaceutical Customer- and Patient-Focused CDMO with the Most Robust and Fastest “Gene to GMP” Service Offering in the Industry

The CDMO of the 21st Century



Selexis SA joins JSR Life Sciences, complementing the 2015 acquisition of KBI Biopharma.

The result: a world-class contract development manufacturing organization (CDMO) for the 21st century

Building the Most Robust & Fastest “Gene to GMP” Service in the BioPharma Industry

Selexis’ best-in-class cell-line development technology solves some of the toughest protein expression challenges in the industry. By combining with KBI’s process development, analytical development, and cGMP manufacturing capabilities, the companies can deliver clinical drug substance within 9 months of receiving the gene of interest.

A Proven History of Collaboration:

- KBI’s analytical expertise has been used to select the best cell lines based on productivity and product quality
- KBI has performed cGMP manufacturing with several Selexis cell lines
- KBI’s mAb, bispecific and fusion platforms have provided titers of 2-10 g/L for 15 Selexis cell lines including GMP manufacturing

The combined CDMO will help biopharma companies to achieve faster time-to-market, to lower manufacturing costs, and to achieve a smoother development pathway even for complex protein products.

In turn, biopharmaceutical companies can deliver better therapeutics to patients suffering from life-threatening conditions like auto-immune and inflammatory diseases, blood disorders and cancers.

Selexis: 15-Year Legacy in Innovative Cell-Line Development Technologies

- Global leader in mammalian (CHO-K1) cell-line generation, with 3 products on the market and over 76 biologic programs to date
- High-yield, stable research cell banks (RCBs)
- Partnerships and collaborations with over 100 industry leaders including:



Merck KGaA
Darmstadt, Germany



KBI Biopharma: Science-Driven, Customer-Focused

- Specializing in contract manufacturing and process development along with deep analytical and formulation development capabilities
- Rapid, integrated process development and cGMP manufacturing programs for a wide range of recombinant proteins
- Expertise in biophysical and biochemical characterization of proteins, with flexible business models
- Partnerships and collaborations with over 250 industry leaders

About JSR Life Sciences Division

JSR Life Sciences Division is a business unit of JSR Corporation, which provides specialized materials and products to the biotech industry. JSR Life Sciences operates a network of manufacturing facilities, sales offices and R&D labs in key markets throughout North America, Europe and AsiaPacific. JSR Life Sciences today is focused on diagnostics and research products and downstream bioprocessing materials for pharmaceutical manufacturing.

About Selexis SA

Selexis SA is a pioneering life sciences company and a global leader in mammalian cell line generation, providing unparalleled proprietary technology and the highly-specialized expertise that is necessary to translate scientific innovation into life-saving medicines for patients. Selexis' SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein. With more than 100 partners worldwide, more than 76 biologic drug development programs and 3 commercial products utilizing its cell lines, Selexis has a history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their research.

About KBI Biopharma

KBI Biopharma, Inc. is a biopharmaceutical Contract Development and Manufacturing Organization that accelerates the development of innovative discoveries into lifechanging biological products. From early-stage to academic/nonprofit organizations, to many of the world's largest pharmaceutical companies, KBI has served 250+ clients globally to accelerate and optimize their drug development programs.